Long-term eliglustat treatment of Gaucher patients over up to 10 years in Vienna

被引：0
作者：
Thomas M. Stulnig
机构：
[1] Clinic Hietzing,Department of Medicine III and Karl Landsteiner Institute for Metabolic Diseases and Nephrology
[2] Vienna Health Care Group,undefined
来源：
Wiener klinische Wochenschrift | 2022年 / 134卷
关键词：
Lysosomal storage disease; Thrombocytopenia; Anemia; Splenomegaly; Biomarkers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Gaucher disease has been the first lysosomal storage disorder for which an enzyme replacement therapy has been approved in the 1990s and was the first to receive approval for a first-line substrate reduction therapy in 2015. Eliglustat treatment has been started in Austria in patients recruited to a clinical trial, followed by its long-term extension and prescription treatment overall covering up to 10 years. In this case series the experience of treating Gaucher patients with eliglustat in Vienna is summarized. Patients were either switched from enzyme replacement therapy or were therapy naïve. Significant improvements were shown in hematological (thrombocytes, hemoglobin) and visceral (spleen volume) manifestations as well as in biomarkers (chitotriosidase, glucosylsphingosine [lyso-GL1], angiotensin converting enzyme) in a routine setting in a therapy-naïve patient. Stability was found in switch patients with slight improvement in bone density. Eliglustat was generally very well tolerated. Patient selection and regular monitoring is required to ensure effective and safe use.
引用
收藏
页码：471 / 477
页数：6
相关论文
共 126 条
  • [1] Stirnemann J(2017)A review of Gaucher disease pathophysiology, clinical presentation and treatments Int J Mol Sci 18 441-e127
  • [2] Belmatoug N(2011)Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response Blood 118 e118-689
  • [3] Camou F(1997)Gaucher’s disease: clinical features and natural history Baillieres Clin Haematol 10 657-440
  • [4] Serratrice C(2014)Gaucher disease: haematological presentations and complications Br J Haematol 165 427-131
  • [5] Froissart R(2003)Extended interval between enzyme therapy infusions for adult patients with Gaucher’s disease type 1 J Postgrad Med 49 127-229
  • [6] Caillaud C(2016)Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients Orphanet J Rare Dis 11 28-899
  • [7] Dekker N(2005)Guidance on the use of miglustat for treating patients with type 1 Gaucher disease Am J Hematol 80 223-706
  • [8] van Dussen L(2010)A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 Blood 116 893-2362
  • [9] Hollak CE(2015)Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial JAMA 313 695-356
  • [10] Overkleeft H(2015)Eliglustat compared with imiglucerase in patients with Gaucher’s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial Lancet 385 2355-32
12345678910